New hope for Tough-to-Treat bile duct cancer
NCT ID NCT06230471
Summary
This study is testing three different first-line treatment combinations for advanced bile duct cancer. It will compare an immunotherapy drug (pembrolizumab) given alone, with chemotherapy, or with another targeted drug (lenvatinib). The goal is to see which approach best controls the cancer, extends life, and is safest for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT NEOPLASMS IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH)
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.